Table 2.
Immunosuppressive treatment according to pathologic diagnosesa
| Minimal change disease or FSGS | Immunoglobulin A nephropathy | Membranous nephropathy | Lupus nephritisb | |
|---|---|---|---|---|
| Number of patients | 67 | 57 | 33 | 31 |
| Proportion of cohort (%) | 29.3 | 24.9 | 14.4 | 13.5 |
| Immunosuppressant | ||||
| Prednisolone | 45 (67.2) | 33 (57.9) | 23 (69.7) | 29 (93.5) |
| Methylprednisolone | 1 (1.5) | 2 (3.5) | 0 (0.0) | 17 (54.8) |
| Calcineurin inhibitor | 14 (20.9) | 6 (10.5) | 7 (21.2) | 2 (6.5) |
| Mycophenolate mofetil or sodium | 7 (10.4) | 11 (19.3) | 7 (21.2) | 27 (87.1) |
| Cyclophosphamide | 2 (3.0) | 1 (1.8) | 8 (24.2) | 7 (22.6) |
Data are presented as number only or number (%).
ANCA, antineutrophil cytoplasmic antibody; FSGS, focal segmental glomerulosclerosis.
a
The four most frequent biopsy diagnoses among the 229 immunosuppressant-naïve non-diabetic adults are shown above, while etiologies including infection-associated glomerulonephritis and ANCA-associated vasculitis constituted the remaining 17.9%. bThe majority of patients with lupus nephritis also received hydroxychloroquine and only 1 received rituximab; none of the other 3 glomerulonephritide patients were treated with rituximab.